Andrew Redfern

Dr

  • The University of Western Australia (M582), 35 Stirling Highway,

    6009 Perth

    Australia

  • 241 Citations
  • 7 h-Index
20122022
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 14 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Nebulizers and Vaporizers Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Epithelial-Mesenchymal Transition Medicine & Life Sciences
Nicotine Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2012 2019

  • 241 Citations
  • 7 h-Index
  • 20 Article
  • 4 Abstract/Meeting Abstract
  • 2 Review article

Hypoxia as a signal for prison breakout in cancer

Redfern, A., Agarwal, V. & Thompson, E. W., 1 Jul 2019, In : Current Opinion in Clinical Nutrition and Metabolic Care. 22, 4, p. 250-263 14 p.

Research output: Contribution to journalArticle

Prisons
Neoplasms
Epithelial-Mesenchymal Transition
Autophagy
Stromal Cells
Breast Neoplasms
Breast Density
Western Australia
Software
Logistic Models
1 Citation (Scopus)

The distribution and determinants of mammographic density measures in Western Australian Aboriginal women

McLean, K., Darcey, E., Cadby, G., Lund, H., Pilkington, L., Redfern, A., Thompson, S., Saunders, C., Wylie, E. & Stone, J., 28 Feb 2019, In : Breast Cancer Research. 21, 1, 11 p., 33.

Research output: Contribution to journalArticle

Open Access
Western Australia
Breast Neoplasms
Breast Density
Economics
Epidemiologic Methods
Open Access
docetaxel
Triple Negative Breast Neoplasms
Nanoparticles
Peptides
Tumors
5 Citations (Scopus)

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial

Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., Semiglazov, V., Thill, M., Ignacio Chacon, J., Chan, A., Morales, S., Alvarez, I., Plazaola, A., Zambetti, M., Redfern, A. D., Dittrich, C., Dent, R. A., Magazzu, D., De Fato, R., Valagussa, P. & 1 othersTusquets, I., Mar 2018, In : JAMA Oncology. 4, 3, p. 302-308 7 p.

Research output: Contribution to journalArticle

Projects 2014 2022